Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study

David M. Kendall, Cindy J. Rubin, Pharis Mohideen, Jean Marie Ledeine, Rene Belder, Jorge Gross, Paul Norwood, Michael O'Mahony, Kenneth Sall, Greg Sloan, Anthony Roberts, Fred T. Fiedorek, Ralph A. DeFronzo

Producción científica: Article › revisión exhaustiva

136 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study'. En conjunto forman una huella única.

Pharmacology, Toxicology and Pharmaceutical Science